Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $1.53
Previous CloseN/A
Volume216.96K
Average Volume (3M)463.42K
Market Cap
$55.71M
Enterprise Value$73.12M
Total Cash (Recent Filing)C$13.70M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 02, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding86,421,590
10 Day Avg. Volume307,095
30 Day Avg. Volume463,422
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)7.20
P/FCF Ratio7.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.82Price Target Upside526.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive final results from the BRACELET-1 trial showed a significant improvement in median overall survival for patients with metastatic breast cancer when treated with pelareorep plus chemotherapy.
Regulatory ProgressOncolytics Biotech is planning to launch a P2 study in breast cancer, with the intent of seeking accelerated approval, following positive feedback from the FDA.
Bears Say
Financial ConcernsOncolytics Biotech is expected to need to raise capital soon to fund its programs, which may lead to potential dilution and has resulted in the lowering of the 12-month price target.
---
Ownership Overview
0.76% Insiders
0.05% Mutual Funds
0.95% Other Institutional Investors
98.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.60 and its highest was $1.53 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $55.71M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is May 02, 2025 which is in 50 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Mar 07, 2025. The company reported -$0.069 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.015.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.07.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 86,421,590 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.069 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went down -6.757%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
---
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.82 (526.23% Upside)
$3.82 (526.23% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.85%
12-Months-Change
Fundamentals
Return on Equity
-184.69%
Trailing 12-Months
Asset Growth
-52.32%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
ONCY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and promising business development efforts, particularly in breast and gastrointestinal cancers. However, financial challenges, leadership transitions, and regulatory uncertainties pose notable concerns.Read More>---
ONCY Stock 12 Month Forecast
Average Price Target
$3.82
▲(526.23% Upside)
Technical Analysis
Best Analysts Covering ONCY
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-17.29%
reiterated a buy rating 4 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -17.29% per trade.
---